



## Symfi®/Symfi Lo® (efavirenz/lamivudine/tenofovir disoproxil fumarate) – First-time generics

- On August 28, 2020, Laurus Labs launched [AB-rated](#) generic versions of Mylan Specialty's [Symfi](#) and [Symfi Lo \(efavirenz/lamivudine/tenofovir disoproxil fumarate\)](#) tablets.
- Symfi is approved as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adult and pediatric patients weighing at least 40 kg.
- Symfi Lo is approved as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adult and pediatric patients weighing at least 35 kg.
- Symfi and Symfi Lo carry a boxed warning for posttreatment acute exacerbation of hepatitis B.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.